Skip to main content
. 2023 Oct 30;35:100768. doi: 10.1016/j.lanepe.2023.100768

Fig. 5.

Fig. 5

All cancer risk (except non-melanoma skin cancer) in rheumatoid arthritis patients according to treatment exposure compared to the general population. csDMARD: conventional disease-modifying antirheumatic drug, TNFi: Tumor necrosis factor inhibitor, JAKi: Janus Kinase inhibitor, SIR: standardized incidence ratio, CI: confidence interval.